Enzyme LytU Boosts Staph Resistance to Vancomycin

Researchers at the University of Jyväskylä found that the enzyme LytU helps Staphylococcus aureus withstand the antibiotic vancomycin.

Updated on Nov. 17, 2026 in Life Sciences

Flat-color editorial illustration of spherical bacterial cells with one cell-wall bridge link pulled apart in red and teal, depicting how a bacterial enzyme weakens an antibiotic's effect.
Researchers at the University of Jyväskylä report that the enzyme LytU helps Staphylococcus aureus withstand vancomycin, one of the antibiotics clinicians rely on most. AI Illustration. Upload story photo >

Researchers have identified an enzyme in Staphylococcus aureus, called LytU, that increases the bacterium's resistance to vancomycin. The study, published in Nature Communications and led by Perttu Permi of the University of Jyväskylä in Finland, found that the enzyme breaks a specific bridge bond in the cell wall structure.

Why it matters

Staphylococcus aureus has already developed resistance to multiple antibiotics, and vancomycin is one of the drugs clinicians rely on against it. Understanding how a cell wall enzyme contributes to that resistance could inform future approaches to preserving the effectiveness of existing treatments.

The evidence comes from laboratory experiments comparing bacteria that produced more LytU against control bacteria, with the resistance difference measured at roughly 30 times. Whether the same effect occurs in clinical isolates outside the lab has not yet been established.

The players

Perttu Permi

Perttu Permi is the researcher who led the study identifying LytU's role in vancomycin resistance, based at the University of Jyväskylä in Finland.

University of Jyväskylä

The University of Jyväskylä is a public research university in Finland, and the institution where the lead author of the LytU study is based.

The details

LytU participates in remodeling the bacterial cell wall by breaking a specific bridge bond involved in cell wall cross-linking, rather than the usual peptidoglycan bonds. The researchers found that LytU activity must be tightly regulated, since excessive enzyme activity disrupted normal cell wall construction.

Timeline

  1. November 17, 2026: The study on LytU and vancomycin resistance was published in Nature Communications.

Legacy Context

The finding extends the story of vancomycin-intermediate Staphylococcus aureus strains first documented in the late 1990s by pointing to a specific cell wall enzyme as a contributor. It suggests that resistance mechanisms identified decades ago may still be incompletely understood.

Any future treatment built on this mechanism would still need to pass laboratory and clinical testing before affecting prescribing. For now, the finding informs research rather than changing how clinicians treat Staphylococcus aureus infections.

The takeaway

Antibiotic resistance often arises from several interacting mechanisms, so identifying a single enzyme like LytU adds a piece to a larger picture. Continued research on bacterial cell wall biology may be important for keeping existing antibiotics effective.

Further reading

For related background, explore Life Sciences coverage on how bacteria evolve resistance to existing drugs.